Industry Reports   Press Room   Blog   About Us

Cell Line Development Market to exceed USD 7.5 bn by 2024

Published Date: September 5, 2018   Author: Global Market Insights, Inc.

Cell Line Development Market size is set to exceed USD 7.5 billion by 2024; according to a new research report by Global Market Insights.
 

Rising incidence of chronic diseases such as cancer, autoimmune disease and inflammatory disorders will drive the global cell line development market during the forecast period. Rapidly growing geriatric population base and unmet need for cancer drugs are the key factors that will fuel the demand for discovery of new drugs, thereby accelerating cell line development industry growth. Increasing adoption of cell line systems for production of vaccines, monoclonal antibodies and lymphokines will boost the demand for cell line cultures. Developments in biotechnology industry coupled with rapidly growing vaccine production across the globe will augment the cell line development market growth.

 

Request Sample Buy NowInquiry Before Buying


 

Advancement in cell line development technologies will serve to be another positive impact rendering factor surging industry growth. Availability of automated screening methods, improved expression systems as well as developments in equipment will further stimulate industry growth. Furthermore, increasing investment in R&D to develop novel technologies and products will upsurge the cell line development market growth. However, stringent regulatory framework for approval of biologics and diagnostic products may hamper the cell line development market growth. Issues related to harvesting human embryonic stem cells that cause destruction of human embryos will further impede the market growth.
 

Equipment segment is estimated to show lucrative CAGR of 13.1% over the forecast period owing to advancements in cell line development technologies. Rapid development in recombinant protein therapeutic products and improvement in speed and ease of cell line production techniques will fuel the demand for incubators, centrifuges, bioreactors, microscopes and other equipment. Increasing need for safety equipment in cell culture laboratories to eliminate exposure to harmful substances will drive the segmental growth in coming years.
 


 

Mammalian segment dominated the cell line development market with 71.7% revenue share in 2017 and will continue to show similar trend during the analysis period. Usage of mammalian cell expression system for production of complex biotherapeutic proteins has increased considerably in recent years. These cell cultures are developed to produce vaccines for various diseases such as mumps, measles and rubella. Growing demand for mammalian cell expression systems in industry as well as research institutes will foster segmental growth in the foreseeable future.

 

Recombinant cell lines segment dominated the cell line development market with USD 1.0 billion revenue in 2017 and is projected to witness healthy growth during the analysis period. Increasing demand for recombinant cell lines due to developments in rDNA technology is the major factor that will drive the segmental growth. Growing utilization of recombinant cell lines for production of biosimilars and monoclonal antibodies will upsurge the segmental growth during the forthcoming years.
 

Drug discovery segment is estimated to witness 12.8% CAGR over the analysis timeframe. The segment growth is highly attributable to development in application of genomics and molecular pharmacology in drug discovery. Growing prevalence of cancer, autoimmune diseases, inflammatory disorders and other chronic diseases will fuel the need for drug discovery. Furthermore, increasing adoption of cell line products for drug screening and lead validation assays will accelerate segmental growth in the coming years.
 

Browse key industry insights spread across 201 pages with 170 market data tables & 12 figures & charts from the report, “Cell Line Development Market Size By Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope}, Accessories & Consumables), By Source (Mammalian, Non-Mammalian {Insects, Amphibians}), By Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), By Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research) Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, France, UK, Spain, Italy, Russia, Japan, China, India, South Korea, Australia, Brazil, Mexico, South Africa, Saudi Arabia), Application Potential, Competitive Market Share & Forecast, 2018 - 2024” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/cell-line-development-market-report
 

U.S. market accounted for USD 1.0 billion in 2017 and is estimated to show similar growth during the analysis period. Increasing prevalence of chronic disease and growing adoption of cell culture techniques are the key factors that will drive the cell line development industry growth. Huge investment in R&D for development of stable cell lines and technological innovations for creating new cell lines will further boost the market growth.  Key industry players in the cell line development market have strong foothold in the U.S. that will elevate the regional growth during the forthcoming years. 
 

Japan market will witness 13.9% CAGR over the forecast timeframe. The growth is attributable to presence of various international pharmaceutical companies developing antibody drugs. Technological developments in stem cell research, clone screening technologies in mammalian cells as well as advancement in protein expression will spur the cell line development market size during the forthcoming years. Moreover, rising government investment in research institutes for development of regenerative medicine will accelerate the regional growth in coming years.
 

Some of the notable industry players operating in global cell line development market include GE Healthcare, Thermo Fisher Scientific, Lonza Group, Sigma-Aldrich Corporation, Wuxi AppTec, Sartorius Stedim Biotech, Corning, Selexis, Vista Biologics, EuBiologics, Paragon Bioservices, Cobra Biologics, Patheon, Samsung Biologics, Epistem Holdings, Catalent, Bioceros, Abzena, Promocell and Cyagen. Key industry players are primarily focusing on partnerships, mergers, acquisitions and new product launch to enhance existing product portfolio as well as maintain their market position. For instance, in November 2016, GE Healthcare collaborated with Valneva SE, a leading vaccine company, with an aim to use Valneva’s EB66 cell-line to optimize virus productivity for producing animal and human health vaccines.
 

Cell Line Development Market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2013 to 2024, for the following segments:

Cell Line Development Market, by product, 2013-2024 (USD Million)

  • Reagents & media
  • Equipment
    • Incubators
    • Centrifuges
    • Bioreactors
    • Storage equipment
    • Microscopes
  • Accessories & consumables

Cell Line Development Market, by source, 2013-2024 (USD Million)

  • Mammalian
  • Non-mammalian
    • Insects
    • Amphibians

Cell Line Development Market, by cell line type, 2013-2024 (USD Million)

  • Recombinant cell lines
  • Hybridomas
  • Continuous cell lines
  • Primary cell lines

Cell Line Development Market, by application, 2013-2024 (USD Million)

  • Bioproduction market
  • Drug discovery
  • Toxicity testing
  • Tissue engineering
  • Research

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa
    • Saudi Arabia